RRP22 is a farnesylated, nucleolar, ras-related protein with tumor suppressor potential

Cancer Research

Volumn 65, Issue 8, 2005, Pages 3117-3125

  Elam, Candice ^a   Hesson, Luke ^b   Vos, Michele D ^a   Eckfeld, Kristin ^a   Ellis, Chad A ^a   Bell, Aaron ^a   Krex, Dietmar ^c   Birrer, Michael J ^a   Latif, Farida ^b   Clark, Geoffrey J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AGAR; FARNESYL TRANS TRANSFERASE; PROTEIN P22; RAS PROTEIN; RAS RELATED PROTEIN P22; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CELL DEATH; CELL GROWTH; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; ENZYME ACTIVITY; FREQUENCY ANALYSIS; HUMAN; HUMAN CELL; METHYLATION; MOLECULAR MECHANICS; NONHUMAN; NUCLEOLUS; NUCLEOTIDE SEQUENCE; ONCOGENE RAS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN LOCALIZATION; TRANSLATION INITIATION; TUMOR SUPPRESSOR GENE;

EID: 20244363084     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-0749     Document Type: Article

References (38)

1. Takai Y, Sasaki T, Matozaki T. Small GTP-binding proteins. Physiol Rev 2001;81:153-208.
2. Khosravi-Far R, Campbell S, Rossman KL, Der CJ. Increasing complexity of Ras signal transduction: involvement of Rho family proteins. Adv Cancer Res 1998;72:57-107.
3. Yu Y, Xu F, Peng H, et al. NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. Proc Natl Acad Sci U S A 1999;96:214-9.
4. Ellis CA, Vos MD, Howell H, Vallecorsa T, Fults DW, Clark GJ. Rig is a novel Ras-related protein and potential neural tumor suppressor. Proc Natl Acad Sci U S A 2002;99:9876-81.
5. Cox AD, Der CJ. Protein prenylation: more than just glue? Curr Opin Cell Biol 1992;4:1008-16.
6. Miyake M, Mizutani S, Koide H, Kaziro Y. Unfarnesylated transforming Ras mutant inhibits the Ras-signaling pathway by forming a stable Ras.Raf complex in the cytosol. FEBS Lett 1996;378:15-8.
7. Williams JG, Drugan JK, Yi GS, Clark GJ, Der CJ, Campbell SL. Elucidation of binding determinants and functional consequences of Ras/Raf-cysteine-rich domain interactions. J Biol Chem 2000;275:22172-9.
8. Porfiri E, Evans T, Chardin P, Hancock JF. Prenylation of Ras proteins is required for efficient hSOS1-promoted guanine nucleotide exchange. J Biol Chem 1994;269:22672-7.
9. Zhu K, Hamilton AD, Sebti SM. Farnesyltransferase inhibitors as anticancer agents: current status. Curr Opin Investig Drugs 2003;4:1428-35.
10. Cox AD, Der CJ. Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras? Biochim Biophys Acta 1997;1333:F51-7.
11. Zucman-Rossi J, Legoix P, Thomas G. Identification of new members of the Gas2 and Ras families in the 22q12 chromosome region. Genomics 1996;38:247-54.
12. Vos MD, Martinez A, Ellis CA, Vallecorsa T, Clark GJ. The pro-apoptotic Ras effector Nore1 may serve as a Ras-regulated tumor suppressor in the lung. J Biol Chem 2003;278:21938-43.
13. Morgenstern JP, Land H. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res 1990;18:3587-96.
14. Vos MD, Ellis CA, Elam C, Ulku AS, Taylor BJ, Clark GJ. RASSF2 is a novel K-Ras-specific effector and potential tumor suppressor. J Biol Chem 2003;278:28045-51.
15. deBlaquiere J, Walker F, Michelangeli VP, Fabri L, Burgess AW. Platelet-derived growth factor stimulates the release of protein kinase A from the cell membrane. J Biol Chem 1994;269:4812-8.
16. Dallol A, Krex D, Hesson L, Eng C, Maher ER, Latif F. Frequent epigenetic inactivation of the SLIT2 gene in gliomas. Oncogene 2003;22:4611-6.
17. Abancay APJ, Gau CL, Machado IM, et al. Identification of dominant negative mutants of Rheb GTPase and their use to implicate the involvement of human Rheb in the activation of p70S6K. J Biol Chem 2003;278, 41:39921-30.
18. Patel G, MacDonald MJ, Khosravi-Far R, Hisaka MM, Der CJ. Alternate mechanisms of ras activation are complementary and favor the formation of ras-GTP. Oncogene 1992;7:283-8.
19. Im E, von Lintig FC, Chen J, et al. Rheb is in a high activation state and inhibits B-Raf kinase in mammalian cells. Oncogene 2002;21:6356-65.
20. Luo RZ, Fang X, Marquez R, et al. ARHI is a Ras-related small G-protein with a novel N-terminal extension that inhibits growth of ovarian and breast cancers. Oncogene 2003;22:2897-909.
21. James GL, Goldstein JL, Brown MS. Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro. J Biol Chem 1995;270:6221-6.
22. Del Villar K, Dorin D, Sattler I, et al. C-terminal motifs found in Ras-superfamily G-proteins: CAAX and C-seven motifs. Biochem Soc Trans 1996;24:709-13.
23. Buss JE, Quilliam LA, Kato K, et al. The COOH-terminal domain of the Rap1A (Krev-1) protein is isoprenylated and supports transformation by an H-Ras:Rap1A chimeric protein. Mol Cell Biol 1991;11:1523-30.
24. Hancock JF. Ras proteins: different signals from different locations. Nat Rev Mol Cell Biol 2003;4:373-84.
25. Farnsworth CL, Feig LA. Dominant inhibitory mutations in the Mg(2+)-binding site of RasH prevent its activation by GTP. Mol Cell Biol 1991;11:4822-9.
26. David-Pfeuty T, Nouvian-Dooghe Y. Human p14(Arf): an exquisite sensor of morphological changes and of short-lived perturbations in cell cycle and in nucleolar function. Oncogene 2002;21:6779-90.
27. Strassheim D, Porter RA, Phelps SH, Williams CL. Unique in vivo associations with SmgGDS and RhoGDI and different guanine nucleotide exchange activities exhibited by RhoA, dominant negative RhoA(Asn-19), and activated RhoA(Val-14). J Biol Chem 2000;275:6699-702.
28. Bao JJ, Le XF, Wang RY, et al. Re-expression of the tumor suppressor gene ARHI induces apoptosis in ovarian and breast cancer cells through a caspase-independent calpain-dependent pathway. Cancer Res 2002;62:7264-72.
29. Noki K, Li Y, Xu T, Guan KL. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev 2003;17:1829-34.
30. Marshall MS. The effector interactions of p21ras. Trends Biochem Sci 1993;18:250-4.
31. James J, Fiordalisi FJ, Johnson RL II, et al. High affinity for farnesyltransferase and alternative prenylation contribute individually to K-Ras4B resistance to farnesyltransferase inhibitors. J Biol Chem 2003;278:41718-27.
32. Tisdale EJ, Bourne JR, Khosravi-Far R, Der CJ, Balch WE. GTP-binding mutants of rab1 and rab2 are potent inhibitors of vesicular transport from the endoplasmic reticulum to the Golgi complex. J Cell Biol 1992;9:749-61.
33. Weber JD, Taylor LJ, Roussel MF, Sherr CJ, Bar-Sagi D. Nucleolar Arf sequesters Mdm2 and activates p53. Nat Cell Biol 1999;1:20-6.
34. Llanos S, Clark PA, Rowe J, Peters G. Stabilization of p53 by p14ARF without relocation of MDM2 to the nucleolus. Nat Cell Biol 2001;3:445-52.
35. Sugimoto M, Kuo ML, Roussel MF, Sherr CJ. Nucleolar Arf tumor suppressor inhibits ribosomal RNA processing. Mol Cell 2003;11:415-24.
36. Ruggero D, Pandolfi PP. Does the ribosome translate cancer? Nat Rev Cancer 2003;3:179-92.
37. Pomeroy SL, Tamayo P, Gaasenbeek M, et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 2002;415:436-42.
38. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042-54.